NEW YORK, July 18 - Lynx Therapeutics reported second-quarter revenues of $4.4 million Wednesday, up 57 percent from the same period last year, and separately said BASF-LYNX, a joint venture with German chemical giant BASF, had agreed to license its Megaclone micro-bead DNA detection technology.

Lynx attributed the increase in revenue primarily to technology access fees that Lynx's customers paid for Megaclone technology. 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The UK's Human Fertility and Embryology Authority calls for consumer genetic testing companies to warn customers that testing could uncover family secrets, according to the Guardian.

The New York Times reports that United Nations delegates have been discussing how to govern the genetic resources of the deep sea.

Researchers have transplanted edited cells into mice that appear to combat cocaine addiction, New Scientist reports.

In PNAS this week: analysis of proteolytic enzymes secreted by circulating tumor cells, phylogenetic study of Fv1 evolution, and more.